Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Recruiting

I'm Interested

Trial ID: NCT02502162,,

Purpose

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Official Title

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Stanford Investigator(s)

Sean Mackey, M.D., Ph.D.
Sean Mackey, M.D., Ph.D.

Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology

Eligibility

Inclusion Criteria:

* Upper and/or lower extremity CRPS
* On stable treatment for 1 month
* CRPS for at least 1 year
* Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria:

* Any known allergy to naltrexone or naloxone
* Use of prescription opioid analgesics or illegal opioid use
* Current or planned pregnancy.

Intervention(s):

drug: LDN

drug: Placebo

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Birute Gedrimaite
650-497-0485